Trevi Therapeutics plans to launch two Phase 2 clinical trials testing Haduvio for chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
Trevi has launched a Phase 2b clinical trial to test Haduvio for the treatment of chronic cough in people with idiopathic pulmonary fibrosis.| Pulmonary Fibrosis News
The FDA application followed trial results that showed NP-120 (ifenprodil) was well tolerated for idiopathic pulmonary fibrosis with cough.| Pulmonary Fibrosis News
Enrollment is now complete in the CORAL clinical trial of nalbuphine ER, to be marketed as Haduvio, for IPF patients with chronic cough.| Pulmonary Fibrosis News
A Phase 2b clinical trial testing Haduvio for IPF cough reached 75% of targeted enrollment but is still recruiting patients in 10 countries.| Pulmonary Fibrosis News
No description.| Pulmonary Fibrosis News
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
Study record managers: refer to the Data Element Definitions if submitting registration or results information.| clinicaltrials.gov
Margarida Maia is a science writer for Pulmonary Fibrosis News with a PhD in biomedical sciences. She covers the latest news and information on a variety of pulmonary fibrosis topics.| Pulmonary Fibrosis News
Category archive page for News.| Pulmonary Fibrosis News
Learn more about the signs, symptoms and complications associated with the debilitating respiratory disease pulmonary fibrosis.| Pulmonary Fibrosis News
Read about idiopathic pulmonary fibrosis (IPF) — its risk factors, symptoms, and current ways of treating this interstitial lung disease.| Pulmonary Fibrosis News
